16 completed, 9 terminated, 6 unknown, 2 withdrawn. 35 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Completed 16, Terminated 9, Unknown 6, Withdrawn 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 3 | Unknown 2, Terminated 1 |
| Phase 3 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow Basiliximab: new trials by email Literature Review of Basiliximab trials Research Report on Basiliximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases Basiliximab - Acute Graft Versus Host Disease, Malignant Hematologic Neoplasm | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 39 | 2024-07-01 | 2024-06-28 |
| Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma Basiliximab, Carmustine, Cytarabine - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 33 | 2021-11-02 | 2025-12-04 |
| Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Basiliximab Injection, Placebo - SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection | Phase 2 | Unknown | Fort Worth Clinical Sciences Working Group | 300 | 2021-10-15 | 2021-08-19 |
| Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL Basiliximab, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 2 | Unknown | Beijing Tongren Hospital | 20 | 2020-06-01 | 2020-04-07 |
| Basiliximab Treating Interstitial Pneumonia of CADM Basiliximab, Calcineurin Inhibitors, Steroids - Lung; Disease, Interstitial, With Fibrosis, Dermatomyositis | Phase 2 | Unknown | RenJi Hospital | 100 | 2017-07-01 | 2017-06-20 |
| Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF) - Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 67 | 2017-05-22 | 2024-12-04 |
| Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant Alpha 1-Antitrypsin, Islet Transplantation, Thymoglobulin - Kidney Transplant, Type 1 Diabetes | Phase 2 | Completed | Massachusetts General Hospital | 2 | 2017-01-01 | 2023-12-22 |
| DC Migration Study for Newly-Diagnosed GBM Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs - Glioblastoma, Astrocytoma, Grade IV | Phase 2 | Completed | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 64 | 2015-10-12 | 2023-06-08 |
| Effect of BM-MSCs in DCD Kidney Transplantation bone marrow-derived mesenchymal stem cells, Saline, Induction therapy (ATG or Basiliximab) - Kidney Transplantation, Acute Kidney Tubular Necrosis | Phase 1 / Phase 2 | Unknown | First Affiliated Hospital, Sun Yat-Sen University | 120 | 2015-10-01 | 2015-09-28 |
| Effect of SVF Derived MSC in DCD Renal Transplantation SVFderived MSC transplantations, Basiliximab - Uremia | Phase 1 / Phase 2 | Unknown | Fuzhou General Hospital | 120 | 2014-12-01 | 2015-07-08 |
| Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) Basiliximab, Methylprednisolone, Prednisone - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Completed | Emory University | 31 | 2013-10-01 | 2017-11-06 |
| Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone - Primary Renal Allograft Candidate, Kidney Transplantation | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 71 | 2013-07-01 | 2026-09-24 |
| A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients ASKP1240, Tacrolimus, Mycophenolate Mofetil (MMF) - Kidney Transplantation | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 149 | 2013-03-05 | 2025-11-21 |
| Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) Simulect®, Neoral®, Certican® - Renal Transplantation | Phase 2 | Completed | Novartis Pharmaceuticals | 16 | 2012-03-01 | 2014-07-25 |
| Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease Infliximab and Basiliximab - Graft Versus Host Disease, Steroid Refractory GVHD | Phase 2 | Terminated | Nationwide Children's Hospital | 11 | 2011-12-01 | 2019-04-05 |
| Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation Alemtuzumab, MMF, Basiliximab - Kidney Transplantation, Renal Transplantation | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 19 | 2011-09-01 | 2026-09-24 |
| Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy Alemtuzumab, Basiliximab, Sirolimus - Kidney Transplantation | Phase 2 / Phase 3 | Completed | University of Oxford | 852 | 2010-09-01 | 2020-04-02 |
| Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation Basiliximab (Simulect), Myfortic, everolimus - Liver Transplantation, Chronic Renal Insufficiency | Phase 2 | Unknown | Armin Goralczyk | 29 | 2010-01-01 | 2011-09-15 |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Basiliximab - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | Indiana University | 17 | 2009-09-01 | 2016-02-26 |
| Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant basiliximab - End Stage Renal Disease | Phase 2 / Phase 3 | Terminated | Drexel University College of Medicine | 5 | 2009-05-01 | 2015-02-10 |
Showing 20 of 35. Sign in to see all of them.
Diabetes Mellitus, Type 1 (6) · Colitis, Ulcerative (2) · Hodgkin Disease (2) · Hypoglycemia (2) · Kidney Failure, Chronic (2) · Amyotrophic Lateral Sclerosis (1) · Anemia, Aplastic (1) · Anemia, Refractory, with Excess of Blasts (1) · COVID-19 (1) · Cytokine Release Syndrome (1) · Dermatomyositis (1) · Disease (1) · Glioblastoma (1) · Graft vs Host Disease (1) · Hematologic Neoplasms (1)
National Institute of Allergy and Infectious Diseases (NIAID) (8) · Cerimon Pharmaceuticals (3) · Astellas Pharma Global Development, Inc. (2) · Anhui Provincial Hospital (1) · Armin Goralczyk (1) · Astellas Pharma Inc (1) · Beijing Tongren Hospital (1) · Bristol-Myers Squibb (1) · City of Hope Medical Center (1) · Drexel University College of Medicine (1) · Emory University (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Fort Worth Clinical Sciences Working Group (1) · Fuzhou General Hospital (1) · Genentech, Inc. (1)
United States (20) · China (4) · United Kingdom (4) · Canada (3) · France (3) · Germany (3) · Italy (2) · Spain (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Czechia (1) · India (1) · Mexico (1)
Kenneth Newell, MD, PhD (2) · Olle Korsgren, MD (2) · A.M. James Shapiro, MD, PhD (1) · Aiman Obed, PD Dr. (1) · Alessandro Rambaldi, MD (1) · Alex F Herrera (1) · Andrew Posselt, MD, PhD (1) · Armin D Goralczyk, Dr. (1) · Bernhard Hering, MD (1) · Camillo Ricordi, MD (1) · Changxi Wang, M.D., Ph.D (1) · Christian P. Larsen, MD, DPhil (1) · Christina N Fournier, MD (1)
PMID 17093248, PMID 18416737, PMID 19663893, PMID 20380712, PMID 20930086, PMID 22549092, PMID 23438305, PMID 23641902, PMID 23738760, PMID 25041339, PMID 25078310, PMID 26285695, PMID 26313245, PMID 26369526, PMID 28556519, PMID 29226570, PMID 29308669, PMID 29963053, PMID 30211831, PMID 31509331, PMID 32558199, PMID 39042770
2008 (2), 2009 (1), P30CA033572 (1), P50CA107399 (1)